A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Virological assessment of hospitalized patients with COVID-2019

Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

(2020) · Nature Communications · doi:10.1101/2020.04.14.20065771 · Cited by 1,019

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature · doi:10.1038/s41586-021-03237-4 · Cited by 694

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster

Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., & Shi, P. (2022) · Nature Medicine · doi:10.1038/s41591-022-02162-x · Cited by 409

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03693-y · Cited by 342

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Cox, M., Peacock, T. P., Harvey, W. T., Hughes, J., Wright, D. W., Willett, B. J., Thomson, E. C., Gupta, R. K., Peacock, S. J., Robertson, D. L., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00809-7 · Cited by 348

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Funari, R., Chu, K.-Y., & Shen, A. Q. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112578 · Cited by 283

Ultrafast, sensitive, and portable detection of COVID-19 IgG using flexible organic electrochemical transistors

Liu, H., Yang, A., Song, J., Wang, N., Lam, P., Li, Y., Law, H., & Yan, F. (2021) · Science Advances · doi:10.1126/sciadv.abg8387 · Cited by 236

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216

Accelerating antiviral drug discovery: lessons from COVID-19

von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00692-8 · Cited by 230

Furin Cleavage Site Is Key to SARS-CoV-2 PathogenesisPreprint

Johnson, B. A., Xie, X., Kalveram, B., Lokugamage, K. G., Muruato, A. E., Zou, J., Zhang, X., Juelich, T. L., Smith, J. K., Zhang, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.268854 · Cited by 186

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

Bian, L., Gao, F., Zhang, J., He, Q., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903879 · Cited by 183

Engineering SARS-CoV-2 using a reverse genetic system

Xie, X., Lokugamage, K. G., Zhang, X., Vu, M. N., Muruato, A. E., Menachery, V. D., & Shi, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 171

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 193

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Zou, J., Kurhade, C., Patel, S., Kitchin, N. R. E., Tompkins, K. R., Cutler, M. W., Cooper, D., Yang, Q., Cai, H., Muik, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2214916 · Cited by 166

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Simon, B., Rubey, H., Treipl, A., Gromann, M., Hemedi, B., Zehetmayer, S., & Kirsch, B. M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab179 · Cited by 151

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies

Vanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134

Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody

Tong, H., Cao, C., You, M., Han, S., Liu, Z., Xiao, Y., He, W., Liu, C., Peng, P., Xue, Z., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114449 · Cited by 151

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126

Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)

Meyer, B., Reimerink, J. H. J., Torriani, G., Brouwer, F., Godeke, G.-J., Yerly, S., Hoogerwerf, M. N., Vuilleumier, N., Kaiser, L., Eckerle, I., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1835448 · Cited by 131

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Higgins, V., Fabros, A., & Kulasingam, V. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.03149-20 · Cited by 125

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Zou, J., Xia, H., Xie, X., Kurhade, C., Machado, R. R. G., Weaver, S. C., Ren, P., & Shi, P. (2022) · Nature Communications · doi:10.1038/s41467-022-28544-w · Cited by 114

Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors

Hua, K., Wang, X., Guo, M., Dai, C., Chen, R., Yang, L., Wu, Y., Ying, T., Zhu, Z., Wei, D., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00837 · Cited by 120

A comparative review of immunoassays for COVID-19 detection

Mohit, E., Rostami, Z., & Vahidi, H. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908886 · Cited by 120

Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

Tang, M. S., Case, J. B., Franks, C. E., Chen, R. E., Anderson, N. W., Henderson, J. P., Diamond, M., Gronowski, A. M., & Farnsworth, C. W. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa211 · Cited by 113

A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers

Liu, R., He, L., Hu, Y., Luo, Z., & Zhang, J. (2020) · Chemical Science · doi:10.1039/d0sc03920a · Cited by 111

The COVID-19 pandemic: viral variants and vaccine efficacy

Ciotti, M., Ciccozzi, M., Pieri, M., & Bernardini, S. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1979462 · Cited by 107

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 106

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors

Zeng, C., Evans, J. P., Pearson, R., Qu, P., Zheng, Y.-M., Robinson, R., Hall‐Stoodley, L., Yount, J. S., Pannu, S. R., Mallampalli, R. K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143213 · Cited by 87

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101

Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays

Sholukh, A. M., Fiore-Gartland, A. J., Ford, E. S., Miner, M. D., Hou, Y. J., Tse, L. V., Kaiser, H., Zhu, H., Lu, J., Madarampalli, B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00527-21 · Cited by 119

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.015 · Cited by 102

Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers

Bayram, A., Demirbakan, H., Karadeniz, P. G., Erdoğan, M., & Koçer, İ. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27098 · Cited by 95

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models

Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J., McAuliffe, J., Kanitkar, A. P., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.001 · Cited by 88

Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment

Hanafy, N. A. N., & El-Kemary, M. A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.073 · Cited by 87

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions

Liu, Y., Zhang, X., Liu, J., Xia, H., Zou, J., Muruato, A. E., Periasamy, S., Kurhade, C., Plante, J. A., Bopp, N. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31930-z · Cited by 92

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

Muruato, A. E., Vu, M. N., Johnson, B. A., Davis-Gardner, M. E., Vanderheiden, A., Lokugamage, K. G., Schindewolf, C., Crocquet-Valdes, P. A., Langsjoen, R. M., Plante, J. A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001284 · Cited by 77

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Oguntuyo, K. Y., Stevens, C. S., Hung, C.-T., Ikegame, S., Acklin, J. A., Kowdle, S., Carmichael, J. C., Chiu, H.-P., Azarm, K. D., Haas, G. D., et al. (2021) · mBio · doi:10.1128/mbio.02492-20 · Cited by 73

A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence

Zhang, X., Liu, Y., Liu, J., Bailey, A. L., Plante, K. S., Plante, J. A., Zou, J., Xia, H., Bopp, N. E., Aguilar, P. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.044 · Cited by 79

The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature

Machado, B. A. S., Hodel, K. V. S., Júnior, V. G. B., Soares, M. B. P., & Badaró, R. J. D. S. (2020) · Viruses · doi:10.3390/v13010040 · Cited by 77

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 74

Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review

Wang, Z., Chen, J., Khan, S. A., Li, F., Shen, J., Duan, Q., Liu, X., & Zhu, J. (2021) · Sensors · doi:10.3390/s22010133 · Cited by 73

Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion

Xue, S., Han, Y., Wu, F., & Wang, Q. (2024) · Protein & Cell · doi:10.1093/procel/pwae007 · Cited by 81

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus

Matusali, G., Colavita, F., Lapa, D., Meschi, S., Bordi, L., Piselli, P., Gagliardini, R., Corpolongo, A., Nicastri, E., Antinori, A., et al. (2021) · Viruses · doi:10.3390/v13040655 · Cited by 68

Recent Advances in Aggregation‐Induced Emission Materials and Their Biomedical and Healthcare Applications

He, W., Zhang, T., Bai, H., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101055 · Cited by 66

Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre‐pandemic controls

Jung, K., Shin, S., Nam, M., Hong, Y. J., Roh, E. Y., Park, K. U., & Song, E. Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23921 · Cited by 64

SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response

Gundlapalli, A. V., Salerno, R. M., Brooks, J. T., Averhoff, F. M., Petersen, L. R., McDonald, L. C., Iademarco, M. F., Response, C. C.-1., Carroll, Y. I., Gorwitz, R. J., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa555 · Cited by 63

Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody

Zhao, T., Liang, P., Ren, J., Zhu, J., Yang, X., Bian, H., Li, J., Cui, X., Fu, C., Xing, J., et al. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341102 · Cited by 62

Antigenic characterization of influenza and SARS-CoV-2 viruses

Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 62

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies

Kohmer, N., Rühl, C., Ciesek, S., & Rabenau, H. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102128 · Cited by 59

Advances in Neutralization Assays for SARS‐CoV‐2

Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 58

Widespread exposure to SARS-CoV-2 in wildlife communities

Goldberg, A. R., Langwig, K. E., Brown, K. L., Marano, J. M., Rai, P., King, K. M., Sharp, A. K., Ceci, A., Kailing, C. D., Kailing, M. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49891-w · Cited by 61

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59

Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody

Liu, K., Han, Y.-J., Wu, G.-H., Huang, K.-Y. A., & Huang, P.-N. (2022) · Viruses · doi:10.3390/v14071560 · Cited by 57

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1

Hu, Y., Zou, J., Kurhade, C., Deng, X., Chang, H. C., Kim, D. K., Shi, P., Ren, P., & Xie, X. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2271089 · Cited by 54

Novel coronavirus disease (COVID-19) pandemic: A recent mini review

Rehman, M. F. U., Fariha, C., Anwar, A., Shahzad, N., Ahmad, M., Mukhtar, S., & Haque, M. F. U. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.033 · Cited by 58

NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies

Wagner, T. R., Kaiser, P. D., Gramlich, M., Ostertag, E., Ruétalo, N., Junker, D., Häring, J., Traenkle, B., Becker, M., Dulovic, A., et al. (2021) · EMBO Reports · doi:10.15252/embr.202052325 · Cited by 50

COVID-19: clinical presentation and detection methods

Pradhan, M., Shah, K., Alexander, A., Ajazuddin, M., Minz, S., Singh, M. R., Singh, D., Yadav, D. K., & Chauhan, N. S. (2021) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2021.1951291 · Cited by 53

Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies

Wang, J. J., Zhang, N., Richardson, S. A., & Wu, J. V. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1913123 · Cited by 49

Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

Tioni, M. F., Jordan, R., Pena, A. S., Garg, A., Wu, D., Phan, S. I., Weiss, C. M., Cheng, X., Greenhouse, J. J., Orekov, T., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00509-6 · Cited by 45

A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds

Schöler, L., Le‐Trilling, V. T. K., Eilbrecht, M., Mennerich, D., Anastasiou, O. E., Krawczyk, A., Herrmann, A., Dittmer, U., & Trilling, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573526 · Cited by 42

COVID-19: molecular and serological detection methods

Dhamad, A. E., & Rhida, M. A. A. (2020) · PeerJ · doi:10.7717/peerj.10180 · Cited by 48

Clinical microbiology in detection and identification of emerging microbial pathogens: past, present and future

Wang, H., Zhang, W., & Tang, Y. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125345 · Cited by 51

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Zou, J., Xie, X., Fontes-Garfias, C. R., Swanson, K. A., Kanevsky, I., Tompkins, K. R., Cutler, M. W., Cooper, D., Dormitzer, P. R., & Shi, P. (2021) · npj Vaccines · doi:10.1038/s41541-021-00313-8 · Cited by 42

Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2

Xia, H., & Shi, P. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.0214 · Cited by 42

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibilityPreprint

Shi, P., Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., et al. (2020) · bioRxiv · doi:10.21203/rs.3.rs-70482/v1 · Cited by 42

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesPreprint

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Hall, M. D., Anderson, J. M., Anderson, A. S., Baker, D. A., Bradner, J. E., Brimacombe, K. R., Campbell, E. A., Corbett, K. S., Carter, K. L., Cherry, S. R., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab305 · Cited by 41

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38

Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?

Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 43

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 VaccinePreprint

Zou, J., Kurhade, C., Patel, S., Kitchin, N. R. E., Tompkins, K. R., Cutler, M. W., Cooper, D., Yang, Q., Cai, H., Muik, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.17.516898 · Cited by 40

Potential medicinal plants to combat viral infections: A way forward to environmental biotechnology

Sharma, R., Bhattu, M., Tripathi, A., Verma, M., Acevedo, R., Kumar, P., Rajput, V. D., & Singh, J. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115725 · Cited by 39

Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination

Huang, L., Li, Y., Luo, C., Chen, Y., Touil, N., Annaz, H. E., Zeng, S., Dang, T., Liang, J., Hu, W., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113868 · Cited by 36

SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications

Toropov, N. A., Osborne, E. L., Joshi, L. T., Davidson, J., Morgan, C., Page, J. W., Pepperell, J., & Vollmer, F. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00612 · Cited by 35

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay

Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E. J., Manguiat, K., Lindsay, L. R., Wood, H., DREBOT, M. A., Dibernardo, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab220 · Cited by 35

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles

Miyakawa, K., Jeremiah, S. S., Ohtake, N., Matsunaga, S., Yamaoka, Y., Nishi, M., Morita, T., Saji, R., Nishii, M., Kimura, H., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa047 · Cited by 34

Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2

Müller, K., Girl, P., von Buttlar, H., Dobler, G., & Wölfel, R. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114122 · Cited by 33

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 34

Immune response against SARS-CoV-2 variants: the role of neutralization assays

Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 34

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 36

Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19

Issa, H., Eid, A. H., Berry, B., Takhviji, V., Khosravi, A., Mantash, S., Nehme, R., Hallal, R., Karaki, H., Dhayni, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.620990 · Cited by 30

Rapid, label-free, and sensitive point-of-care testing of anti-SARS-CoV-2 IgM/IgG using all-fiber Fresnel reflection microfluidic biosensor

Xu, W., Liu, J., Song, D., Li, C., Zhu, A., & Long, F. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04911-0 · Cited by 32

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Bonanni, P., Cantón, R., Gill, D., Halfon, P., Liebert, U. G., Crespo, K. A. N., Martín, J. J. P., & Trombetta, C. M. (2021) · COVID · doi:10.3390/covid1010004 · Cited by 36

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

Wagner, A., Guzek, A., Ruff, J., Jasińska, J., Scheikl, U., Zwazl, I., Kundi, M., Stockinger, H. S. J., Farcet, M. R., Kreil, T. R., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00012-4 · Cited by 28

Identifying optimal capsid duplication length for the stability of reporter flaviviruses

Baker, C. K., Liu, Y., Zou, J., Muruato, A. E., Xie, X., & Shi, P. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1829994 · Cited by 30

Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip

Wang, C., Wang, C., Qiu, J., Gao, J., Liu, H., Zhang, Y., & Han, L. G. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04896-w · Cited by 30

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 29

Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies

Kim, S. J., Yao, Z., Marsh, M., Eckert, D. M., Kay, M. S., Lyakisheva, A., Pasic, M. D., Bansal, A., Birnboim, C., Jha, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31300-9 · Cited by 28

Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsPreprint

Sholukh, A. M., Fiore-Gartland, A., Ford, E. S., Hou, Y., Tse, L.-P. V., Lempp, F., Kaiser, H., Germain, R. S., Bossard, E. L., Jia, J.-K., et al. (2020) · medRxiv · doi:10.1101/2020.12.07.20245431 · Cited by 25

SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease

Gniadek, T. J., Thiede, J. M., Matchett, W. E., Gress, A. R., Pape, K. A., Fiege, J. K., Jenkins, M. K., Menachery, V. D., Langlois, R. A., & Bold, T. D. (2020) · Transfusion · doi:10.1111/trf.16101 · Cited by 28

Nanoplasmonic multiplex biosensing for COVID-19 vaccines

Funari, R., Fukuyama, H., & Shen, A. Q. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114193 · Cited by 27

SARS-CoV-2 serology testing: Progress and challenges

Shi, A. C., & Ren, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113060 · Cited by 28

Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

Bennett, R. S., Postnikova, E. N., Liang, J. Y., Gross, R., Mazur, S., Dixit, S., Lukin, V. V., Kocher, G., Yu, S., Georgia, S., et al. (2021) · Viruses · doi:10.3390/v13050893 · Cited by 29

Development of a SARS-CoV-2 monoclonal antibody panel and its applicability as a reagent in high-throughput fluorescence reduction neutralization and immunohistochemistry assaysPreprint

Coelho, G. M., Cataneo, A. H. D., Raboni, S. M., Nogueira, M. B., de Paula, C. B. V., Almeida, A. C., Rogerio, V. Z., Zanchin, N. I. T., de Noronha, L., Zanluca, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.29.542720

A flow cytometry‐based assay to measure neutralizing antibodies against SARS‐CoV ‐2 virus

Pscheidt, V. M., de Souza, P. O., Fazolo, T., Proença‐Módena, J. L., Simeoni, C. L., de Toledo-Teixeira, D. A., Brunetti, N. S., Bispo-dos-Santos, K., Júnior, L. R., & Bonorino, C. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24838 · Cited by 1

Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays

Coelho, G. M., Cataneo, A. H. D., Raboni, S. M., Nogueira, M. B., de Paula, C. B. V., Almeida, A. C., Rogerio, V. Z., Zanchin, N. I. T., de Noronha, L., Zanluca, C., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29111 · Cited by 3

A Novel Adaptive Platform for Rapid, Simple Flow-Based Antibody Detection Devices Predicts NAb Levels to SARS-CoV-2

Markmann, A., Bhowmik, D. R., Jiang, B., Vanna, U. P., Hoy, M. V., Wang, F., Hou, Y., Margolis, D., Baric, R. S., de Silva, A., et al. (2026) · Pathogens and Immunity · doi:10.20411/pai.v11i1.910